Additionally, in the mouse model of valosin-containing protein (VCP) myopathy, MCC950 improved the physical performance of mice by inhibiting the activation of the NLRP3 inflammasome, which has an effective therapeutic potential in the treatment of VCP-related myopathy (90). This evidence concerns the gene NLRP3 and myopathy.